Resolution criteria

This market will resolve to YES if, by December 31, 2039, artificial intelligence systems have autonomously taken over a significant, core portion of clinical primary care medicine. Specifically, this requires at least one of the following conditions to be met:

1. Autonomous Prescribing/Treatment: Legally authorized AI systems in at least one major country (e.g., US, UK, EU, Canada, Japan) are permitted to independently diagnose and prescribe or adjust prescription medications for common primary care conditions (e.g., hypertension, diabetes, simple infections) without requiring a human physician's sign-off, co-signature, or active case-by-case review, and this is actively implemented in clinical practice.

2. Consensus/Data-Driven Benchmarks: A reputable medical or healthcare policy organization (e.g., American Medical Association, American Academy of Family Physicians, National Academy of Medicine, or equivalent) or a peer-reviewed study in a top-tier medical journal (e.g., JAMA, The Lancet, NEJM) reports that 30% or more of standard clinical tasks, diagnostics, or patient consultations in primary care are handled fully autonomously by AI.

3. Autonomous Clinical Pathways: The FDA or equivalent regulatory bodies have cleared/approved autonomous clinical AI agents for at least three distinct diagnostic/treatment pathways in primary care that bypass the need for a human clinician's judgment.

For the purposes of this market:

• "Fully autonomous" means the AI makes the clinical decision and takes action (e.g., diagnostic output, prescription issuance) on its own authority, rather than acting as a decision-support tool or administrative assistant (e.g., AI scribes, coding, or scheduling automation do not qualify).

• If the above conditions are not met, or if AI remains restricted purely to administrative tasks and human-in-the-loop clinical decision support, the market will resolve to NO.

• In the event of ambiguity, the market creator will resolve the market using reliable consensus reports from established healthcare policy institutions.

Background

The integration of artificial intelligence in primary care has historically progressed along two tracks: administrative automation (such as AI scribes reducing charting time) and narrow, specialized diagnostic tasks (such as the 2018 FDA clearance of LumineticsCore/IDx-DR for autonomous diabetic retinopathy screening in primary care clinics).

While AI has optimized workflows, clinical decision-making and independent prescribing have remained heavily human-dependent due to regulatory, legal, and safety frameworks. As physician shortages increase and generative AI models advance, proposals for "agentic" clinical AI—systems capable of managing patient care over multi-step processes with minimal oversight—are being actively researched. However, widespread structural replacement of human primary care physicians remains constrained by the necessity of physical exams, complex diagnostics, and patient trust. This market asks whether these structural barriers will be fully overcome to automate core clinical roles by 2039.

This description was generated by AI. Review and verify everything here yourself. You can edit, replace, or delete any part of this description, including the resolution criteria. You do not need to trust the AI output.